|1.||Clement, Joachim H: 4 articles (11/2008 - 06/2005)|
|2.||Müller, Werner E G: 3 articles (02/2014 - 01/2013)|
|3.||Schröder, Heinz C: 3 articles (02/2014 - 01/2013)|
|4.||Wang, Xiaohong: 3 articles (02/2014 - 01/2013)|
|5.||Jensen, Ole T: 3 articles (12/2013 - 01/2012)|
|6.||Raida, Martin: 3 articles (11/2005 - 06/2005)|
|7.||Harris, Adrian L: 3 articles (11/2005 - 06/2005)|
|8.||Vitters, E L: 2 articles (06/2015 - 12/2007)|
|9.||van de Loo, F A J: 2 articles (06/2015 - 12/2007)|
|10.||van der Kraan, P M: 2 articles (06/2015 - 12/2007)|
11/01/2014 - "Bone morphogenetic protein 2 (BMP2) plays important roles in cancer cell signalings (Vecht et al. Oncologist 19:751-9, 2014). "
08/01/2014 - "Bone morphogenetic protein 2 (BMP2) is a growth factor that is involved in the development and progression of various types of cancer. "
02/01/2010 - "Viral vector-induced expression of bone morphogenetic protein 2 produces inhibition of tumor growth and bone differentiation of stem cells."
11/01/2008 - "Differential expression of cancer-related genes by single and permanent exposure to bone morphogenetic protein 2."
02/02/2006 - "Bone morphogenetic protein 2 stimulation of tumor growth involves the activation of Smad-1/5."
|2.||Breast Neoplasms (Breast Cancer)
08/01/2014 - "Aberrant promoter DNA methylation inhibits bone morphogenetic protein 2 expression and contributes to drug resistance in breast cancer."
02/01/2012 - "Bone morphogenetic protein 2 (BMP2) has been shown to modulate the proliferation and differentiation of breast cancer cells. "
07/01/2008 - "Bone morphogenetic protein 2 (BMP-2) is a key mediator of physiologic bone formation and pathologic vasculature calcification, but its role in breast cancer microcalcification is unknown. "
07/01/2008 - "Humoral bone morphogenetic protein 2 is sufficient for inducing breast cancer microcalcification."
06/01/2005 - "Expression of bone morphogenetic protein 2 in breast cancer cells inhibits hypoxic cell death."
10/01/2012 - "The gold standard of clinical bone reconstruction therapy with a physiologically active material is treatment with recombinant human bone morphogenetic protein 2 (BMP2); however, this approach has limitations, such as inflammation, poor cost-efficiency, and varying interindividual susceptibility. "
11/01/2012 - "There is growing evidence that the metabolism of bone as well as the cartilage damage associated with the above disease processes are strongly inter-related with the interactions of the inflammation-related pathways (in particular prostaglandin E₂ (PGE₂)) and osteogenesis (in particular bone morphogenetic protein-2 (BMP-2)). "
05/01/2011 - "High doses of bone morphogenetic protein 2 induce structurally abnormal bone and inflammation in vivo."
10/01/2014 - "Quantitative RNA analysis resulted in no differences with regard to several markers of calcifying degeneration (alkaline phosphatase, osteopontin, osteocalcin, osteoprotegerin, bone morphogenetic protein-2, runt-related transcription factor-2) and inflammation (tumor necrosis factor α, interleukin 1β, receptor for advanced glycation end products, CD39, CD73), but significantly lower levels of interleukin-6 in group S. "
|4.||Heterotopic Ossification (Ectopic Ossification)
08/01/2006 - "Possible involvement of bone morphogenetic protein 2 in heterotopic ossification in metastatic lesion from urothelial carcinoma of bladder."
12/01/2008 - "We describe four cases of heterotopic ossification in patients treated with either recombinant bone morphogenetic protein 2 or recombinant bone morphogenetic protein 7. We found that while some patients were asymptomatic, heterotopic ossification which had occurred around a joint often required operative excision with good results."
|1.||Bone Morphogenetic Protein 7
|2.||Messenger RNA (mRNA)
|3.||Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)
|5.||Transforming Growth Factor beta1 (TGF beta 1)
|6.||Bone Morphogenetic Protein Receptors
|7.||Fibroblast Growth Factor 2 (Basic Fibroblast Growth Factor)
|8.||Proteins (Proteins, Gene)
|9.||Glial Cell Line-Derived Neurotrophic Factor (GDNF)
|10.||S100 Proteins (S 100 Protein)
|3.||Free Tissue Flaps
|5.||Prostheses and Implants (Prosthesis)